| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
Anticoagulant drug monitoring
A growing menu of assays
There are an increasing number of direct oral anticoagulants (DOACs) and direct thrombin inhibitors (DTI) available on the market. With increasing clinical utilization, drug level monitoring needs also have increased. Some DOACs and DTIs require routine monitoring, while others are monitored in more select clinical situations. The Special Coagulation Laboratory at Mayo Clinic offers clients access to a growing menu of special coagulation drug assays.
Key testing
APIXA | Apixaban, Anti-Xa, Plasma
ARGAT | Argatroban, Ecarin, Plasma
RIVAR | Rivaroxaban, Anti-Xa, Plasma
Special considerations in the use of direct oral anticoagulants (DOACs)
This virtual lecture focuses on special considerations in the use of DOACs. Ariela Marshall, M.D., discusses treatment of cancer-associated venous thromboembolism (VTE) and the outcomes of DOACs as well as DOAC and antiphospholipid syndrome (APS) and heparin-induced thrombocytopenia (HIT). Then, Waldemar Wysokinski, M.D., Ph.D., discusses the reversal of DOACs and outcomes.